Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
Y H Park, E Senkus-Konefka, S-A Im, G Pentheroudakis, S Saji, S Gupta, H Iwata, M Y Mastura, R Dent, Y-S Lu, Y Yin, B K Smruti, T Toyama, S Malwinder, S C Lee, L-M Tseng, J H Kim, T-Y Kim, K J Suh, F Cardoso, T Yoshino, J-Y Douillard, Y H Park, E Senkus-Konefka, S-A Im, G Pentheroudakis, S Saji, S Gupta, H Iwata, M Y Mastura, R Dent, Y-S Lu, Y Yin, B K Smruti, T Toyama, S Malwinder, S C Lee, L-M Tseng, J H Kim, T-Y Kim, K J Suh, F Cardoso, T Yoshino, J-Y Douillard
Abstract
In view of the planned new edition of the most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of primary breast cancer published in 2015, it was decided at the ESMO Asia Meeting in November 2018, by both the ESMO and the Korean Society of Medical Oncology (KSMO), to convene a special face-to-face guidelines meeting in 2019 in Seoul. The aim was to adapt the latest ESMO 2019 guidelines to take into account the ethnic and geographical differences associated with the treatment of early breast cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with early breast cancer representing the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO) Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices, and the drug availability and reimbursement situations, in the individual participating Asian countries.
Keywords: ESMO guidelines; Pan-Asian; consensus; early breast cancer.
Conflict of interest statement
Disclosure FC has received fees for consultancy/advisory roles from Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Medspace, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Seatlle Genetics and Teva. RD has received fees for consultancy/advisory roles from AstraZeneca, Eisai, Lilly, Merck, Novartis, Pfizer, Roche, and for travel and subsistence from Roche, Merck, Pfizer, Eisai. SG has received research funding from Roche, Sanofi, Johnson & Johnson, Oncostem, Amgen, Celltrion, Novartis, Eisai, Intas and Biocon. S-AI has received fees for consultancy/advisory roles from Amgen, AstraZeneca, Hanmi Corp, Medpacto, Pfizer, Eisai, Novartis, Roche and Lilly, and research funding from AstraZeneca, Pfizer and Roche. HI has received fees for consultancy/advisory roles from Chugai, AstraZeneca, Lilly, Daiich-Sankyo, Pfizer, MSD, Eisai, Kyowa Hakko Kirin, Taiho and Novartis, and research funding from Chugai, AstraZeneca, Lilly, Daiich-Sankyo, Pfizer, MSD, Kyowa Hakko Kirin, Bayer, Novartis and GSK. JHK has received research funding from Ono Pharma Korea Co., Ltd. SCL has received fees for consultancy/advisory roles from Roche, Pfizer, Novartis, Eli Lilly, AstraZeneca and research funding from Taiho, ACT Genomics, Eisai and Pfizer. Y-SL has received fees for consultancy/advisory roles from Pfizer, MSD, Novartis, Boehringer-Ingelheim and Roche, and research funding from MSD, Novartis and Roche. SM has received fees for consultancy/advisory roles from MSD and research funding from ASLAN Pharmaceuticals, MSD, Novartis, Astellas and AstraZeneca. MYM has received research funding from MSD, Mundi Pharma, Astellas, Novartis, AstraZeneca, Sanofi, Roche and Pfizer. YHP has received fees for consultancy/advisory roles from AstraZeneca, Pfizer, Eisai, Novartis, Merck, Roche and Lilly, and research funding from AstraZeneca, Eisai, Merck, Pfizer, Novartis and Roche. GP has received fees for consultancy/advisory roles from Roche, Amgen, MSD, Boehringer and Bristol-Myers Squibb, and research funding from Roche, Amgen, Astellas, Pfizer and Novartis. SS has received fees for consultancy/advisory roles from Novartis, Chugai and Kyowa Kirin, research funding from Chugai, Takeda, Eisai, Taiho and Novartis, and fees for non-CME services received directly from commercial interests or their agents (e.g. speakers bureau) from Pfizer, Novartis, AstraZeneca, Eli Lilly, Eisai, Kyowa Kirin and Chugai, and is an executive board member of the Japan Breast Cancer Society (JBCS) and the Japan Breast Cancer Research Group (JBCRG). ES has received honoraria from Amgen, AstraZeneca, Clinigen, EGIS Pharmaceuticals, Eli Lilly, Genomic Health, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz and TLC Biopharmaceuticals, travel support from Amgen, AstraZeneca, EGIS Pharmaceuticals, Novartis, Pfizer and Roche, and clinical research funding from Amgen, AstraZeneca, Boehringer, Eli Lilly, Merck, Novartis, Pfizer, Roche and Samsung. BKS has received fees for consultancy/advisory roles from Eli Lilly, Dr Reddy's Lab, Cipla and AstraZeneca. TT has received fees for consultancy/advisory roles from AstraZeneca and research funding from Eisai, Chugai, and Novartis Pharma. TY has received research funding from Novartis Pharma K.K., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Sanofi K.K., Daiichi Sankyo Co., Ltd., Parexel International Inc., ONO Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Boehringer Ingleheim Japan, Inc. J-YD, T-YK, KJS, L-MT and YY have declared no conflicts of interest.
Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.
Source: PubMed